Dr. Mary Claire Haver on Women's HRT: Press Coverage, Public Statements, and Clinical Context

Who Is Dr. Mary Claire Haver?

Mary Claire Haver is a board-certified obstetrician-gynecologist based in Texas who has practiced for over two decades. She founded The Pause Life, an educational platform dedicated to menopause health, and published The New Menopause in 2024, which reached the New York Times bestseller list within its first week. Her clinical and public work centers on one argument: menopausal women deserve better care than they currently receive.

Medical Training and Background

Haver completed her OB-GYN residency and has maintained board certification throughout her career. She has repeatedly noted in interviews that her own residency training included almost no formal education on menopause management. A 2023 survey published in Menopause found that only 31.3% of OB-GYN residency programs offered a menopause medicine curriculum [1]. This training gap is a recurring theme in her public advocacy.

Rise as a Public Educator

Her social media presence grew rapidly beginning in 2021, when short-form videos explaining perimenopause symptoms and hormone therapy options attracted millions of views. By 2025, her combined following across Instagram and TikTok had exceeded four million. The audience growth reflects a broader cultural shift: a 2024 Kaiser Family Foundation poll found that 40% of women aged 50 to 64 reported difficulty getting adequate menopause care from their providers [2].

Key Public Statements on Hormone Therapy

Haver's press coverage spans television, longform podcasts, print media, and her own platforms. Her core clinical positions have remained consistent across these appearances. She advocates for menopausal hormone therapy when the benefit-risk profile is favorable, and she is critical of the prolonged chilling effect the 2002 Women's Health Initiative (WHI) results had on prescribing.

The WHI Reinterpretation

In multiple interviews, including her 2024 appearance on The Huberman Lab, Haver has discussed the WHI at length. She has stated that the original WHI headlines overstated the risks of hormone therapy for younger menopausal women. The data supports this interpretation. A reanalysis of the WHI estrogen-alone arm published in JAMA showed that women aged 50 to 59 who received conjugated equine estrogen had a lower risk of coronary heart disease (hazard ratio 0.59, 95% CI 0.38 to 0.90) compared to placebo [3]. The absolute risk increase for breast cancer in the combined estrogen-progestin arm was 8 additional cases per 10,000 woman-years [4].

Haver has been careful to specify that the WHI used oral conjugated equine estrogen and medroxyprogesterone acetate, not the transdermal estradiol and micronized progesterone that many clinicians now prefer. This is a distinction the Endocrine Society's 2015 scientific statement also emphasizes [5].

Personal Use of HRT

Haver has disclosed publicly that she uses menopausal hormone therapy herself. On The Diary of a CEO podcast (2024), she stated, "I take estradiol and progesterone. I started when I became symptomatic in my late 40s." She has described her own experience with vasomotor symptoms, brain fog, and joint pain as motivators for both her personal treatment decision and her advocacy work.

This disclosure is notable because physician self-disclosure about hormone use remains uncommon in mainstream media. It does not constitute a clinical recommendation, but Haver has used it to normalize the conversation around treatment. She has always paired this personal detail with the qualifier that HRT decisions must be individualized.

Criticism of the "Menopause Care Gap"

A central theme in Haver's press appearances is what she calls the "menopause care gap." She argues that the combination of inadequate residency training, post-WHI fear, and cultural dismissal of menopausal symptoms has left millions of women without access to effective treatment. The North American Menopause Society (NAMS) 2022 position statement supports this framing, noting that "for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" [6].

In a 2024 Today Show segment, Haver cited data showing that prescriptions for menopausal hormone therapy in the United States dropped by roughly 80% between 2002 and 2012 following the initial WHI publication. Prescribing rates have only partially recovered. A 2020 analysis in Menopause documented that MHT use among U.S. Women fell from 22.4% in 1999 to 4.7% by 2010, with a slight rebound to approximately 5.2% by 2018 [7].

Clinical Positions: What Haver Recommends and What the Evidence Shows

Haver's public recommendations map closely to current guideline-based practice. She is not an outlier. Her visibility has made her a polarizing figure in some circles, but her stated positions on estrogen, progesterone, and testosterone are within the mainstream of menopause medicine.

Estradiol and Progesterone

Haver has consistently recommended transdermal estradiol over oral conjugated estrogens, citing a lower risk of venous thromboembolism (VTE). A 2019 BMJ nested case-control study found that transdermal estrogen was not associated with increased VTE risk (adjusted odds ratio 0.93, 95% CI 0.87 to 1.01), while oral estrogen carried an adjusted odds ratio of 1.58 (95% CI 1.52 to 1.64) [8]. This distinction appears in nearly every media interview she gives on the subject.

For progestogen therapy in women with a uterus, Haver favors micronized progesterone (Prometrium) over synthetic progestins. The PEPI trial (N=875) demonstrated that micronized progesterone preserved the beneficial effects of estrogen on HDL cholesterol more effectively than medroxyprogesterone acetate [9]. The 2019 Lancet meta-analysis of worldwide epidemiological evidence found that estrogen-only MHT carried a lower breast cancer risk (RR 1.17, 95% CI 1.10 to 1.26) than combined estrogen-progestogen therapy (RR 1.60, 95% CI 1.52 to 1.69) after 5+ years of use, though the absolute risk remained small [10].

Testosterone for Women

Haver has discussed off-label testosterone therapy for postmenopausal women, particularly for hypoactive sexual desire. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in 2019 across four journals, concluded that testosterone in physiologic female doses "may be considered for postmenopausal women with HSDD after exclusion of other causes" [11]. No FDA-approved testosterone product for women exists in the United States, a point Haver has raised as evidence of a systemic gap in women's health pharmacotherapy.

Addressing Bone and Cardiovascular Risks

In her book and interviews, Haver discusses the skeletal and cardiovascular benefits of MHT for women who initiate therapy near menopause onset. The WHI data showed that estrogen therapy reduced hip fracture risk (HR 0.61, 95% CI 0.41 to 0.91 in the estrogen-alone arm) [3]. She has also referenced the "timing hypothesis," supported by the Kronos Early Estrogen Prevention Study (KEEPS), which found that early-initiated transdermal estradiol was associated with less progression of carotid intima-media thickness compared to placebo over 4 years [12].

Haver does not present these as reasons to start HRT in asymptomatic women for prevention alone. She has stated in interviews, "We don't prescribe hormones just for bone health or heart protection. But if a woman is symptomatic and we are already treating her, these are real, measurable benefits she should know about."

Media Appearances and Press Coverage

Haver's media trajectory accelerated between 2023 and 2025. Her appearances span formats that reach different audiences.

Television and Print

She has appeared on Today, Good Morning America, and CBS Mornings, typically in segments lasting 4 to 8 minutes focused on menopause symptoms and treatment access. The New York Times profiled her in a 2024 feature examining the new wave of menopause advocates. The Washington Post and The Atlantic have both cited her as a leading voice in the movement to normalize menopause care.

Podcast Appearances

Her longest-form discussions have appeared on The Huberman Lab (2024, approximately 2.5 hours), The Diary of a CEO (2024), The Doctor's Farmacy with Mark Hyman, and The Peter Attia Drive. These conversations allowed her to discuss clinical nuances, including VTE risk stratification, the difference between bioidentical and synthetic hormones, and the regulatory status of compounded hormones, in a level of detail that television does not permit.

Social Media Strategy

Haver's TikTok and Instagram content follows a pattern: short videos (60 to 180 seconds) that name a specific symptom, explain the hormonal mechanism, and describe a treatment option. This format is deliberately structured to counter what she calls the "just deal with it" response many women receive from their physicians. A 2023 cross-sectional study in JAMA Network Open found that social media was the primary information source for menopause-related health information for 34.2% of women surveyed [13].

Criticism and Controversy

No public health figure with Haver's reach operates without scrutiny. Several criticisms have been directed at her work, some clinical and some structural.

Oversimplification Concerns

Some clinicians have argued that short-form social media cannot adequately communicate the individualized risk-benefit analysis that MHT requires. This is a valid concern. Haver has responded by emphasizing that her social media content is educational, not prescriptive, and that she directs viewers to seek care from menopause-trained clinicians. The NAMS "Find a Menopause Practitioner" directory, which she frequently references, lists certified providers across the United States [6].

Compounded Hormone Therapy

Haver has discussed compounded bioidentical hormones in some appearances, which has drawn criticism from physicians who note that compounded products lack the regulatory oversight of FDA-approved formulations. The FDA and NAMS both advise caution with compounded hormones, recommending FDA-approved products when available [14]. Haver has acknowledged this distinction in her book, noting that compounding may be necessary when FDA-approved options do not meet a patient's needs, while also stating that FDA-approved formulations should be the first choice.

Commercial Interests

As with any physician who builds a consumer-facing brand, questions about commercial influence arise. Haver sells courses and supplements through The Pause Life. She has stated that her clinical recommendations are not influenced by her business interests, and her core positions on MHT align with published guidelines rather than proprietary products.

What This Means for Patients Considering HRT

Haver's public work has measurably increased awareness of menopausal hormone therapy as a treatment option. For patients considering MHT, her statements are best understood as aligned with, not a substitute for, guideline-based care.

Who Is a Candidate?

Per the 2022 NAMS position statement, MHT is appropriate for symptomatic women under 60 or within 10 years of menopause onset who have no contraindications (personal history of breast cancer, active liver disease, unexplained vaginal bleeding, or history of VTE with oral estrogen) [6]. The Endocrine Society recommends transdermal estradiol at the lowest effective dose [5].

Finding a Provider

NAMS certification is the most recognized credential for menopause medicine in the United States. Patients can search the NAMS practitioner directory at menopause.org. Haver has emphasized this step repeatedly: "Finding someone who actually trained in this is the single most important thing you can do."

The 2022 NAMS position statement recommends that clinicians reassess MHT annually, with no arbitrary time limit for discontinuation, as long as the benefit-risk profile remains favorable [6].